Retatrutide 5mg+cagrilintide 5mg

Compound Overview

Research Use Only. Not for Human Consumption.

Retatrutide 5mg+cagrilintide 5mg is supplied by Nexus as a Nexus-only multi-peptide research blend for controlled in-vitro laboratory workflows. The catalog configuration is a 10mg total blend, with 5mg assigned to the retatrutide component and 5mg assigned to the cagrilintide component.

The supplied research record classifies this item as a multi-peptide blend in the GLP-1 & Metabolic category. It is described as a dual-incretin/amylin-pathway research blend, with retatrutide identified as the triple agonist peptide component and cagrilintide identified as the amylin analog component. Because the item is a blend rather than a single isolated compound, the provided data does not assign a single CAS number, molecular formula, molecular weight, or sequence to the finished vial.

The available source data for this blend is intentionally limited. This page does not add unsupported component chemistry, published citations, sequence data, purity values, batch identifiers, dosage guidance, or biological outcome claims. Component-specific chemistry should be reviewed through the individual retatrutide and cagrilintide records where those records are available.

Research Background & Published Literature

The research source identifies RC10 as a Nexus-only blend combining a retatrutide component and a cagrilintide component. The product-level record does not include blend-specific peer-reviewed citations, clinical claims, component sequences, or a product-specific literature bibliography. For that reason, this description stays at the catalog and analytical-verification level rather than extending into unsupported mechanistic detail.

At the component level, the record provides only the following research classifications: retatrutide is listed as a triple agonist peptide component, and cagrilintide is listed as an amylin analog component. The blend is categorized for GLP-1 and metabolic research workflows, but the supplied data does not provide a validated experimental protocol, target concentration, assay design, or intended model system. Researchers should treat this page as a product identity and handling summary, not as a literature review or experimental-methods guide.

No product-specific citations were supplied in the research data for this blend. To avoid filling source gaps with guesses, no citations are listed here.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Jastreboff et al. (2023) — N Engl J Med
• Enebo et al. (2021) — Lancet

Storage, Handling & Stability Guidelines

Use the applicable lot/source record for storage of unopened material. Any diluent selection, preparation, temperature, aliquoting, or post-reconstitution hold conditions must be established by a qualified laboratory under a validated SOP; this page does not establish a stability window.

• Keep the lyophilized vial sealed until it is ready for controlled laboratory preparation.
• Protect stored material from moisture and direct light exposure.
• Use a validated laboratory SOP and the applicable lot/source record for any preparation or post-reconstitution handling.
• Label prepared aliquots with compound name, reconstitution date, operator initials, and any laboratory-specific tracking identifiers.
• Follow institutional procedures for handling research peptides and lyophilized laboratory reagents.

Quality Assurance & Lab Verification

The Certificate of Analysis for this catalog item is pending. No provisional batch, assay, method, analyst, or release data is published in this product dossier. Check the Lab Verified archive for documentation status.